June 26, 2012

Provectus Pharmaceuticals Presents Final Phase 2 on PV-10 At 2nd European Post-Chicago Melanoma Meeting 2012 on June 22, 2012

Today, the company released Dr. Agarwala's presentation of top-line final data from Provectus' MM Phase 2 clinical trial at the 2nd European Post-Chicago Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma in Munich, which was made this past Friday.

I will be blogging my analysis of the data, information gathering and due diligence in several posts.

PV-10 will be approved for Stage 3 melanoma (focused regulatory label). As soon as PV-10 is approved, the drug will be used for Stage 2 and 4 disease.

No comments:

Post a Comment